Search filters
Reimbursement Scheme Mounjaro KwikPen® for the indication Diabetes Mellitus type 2

Reimbursement Scheme Mounjaro KwikPen® for the indication Diabetes Mellitus type 2

06/11/2024

The health insurer does not fully reimburse Mounjaro KwikPen for the indication Diabetes Mellitus type 2. The producer of this...

Reimbursement Scheme Veoza®

Reimbursement Scheme Veoza®

01/05/2024

Reimbursement Scheme for VEOZA® (fezolinetant) 45 mg for the treatment of moderate to severe vasomotor symptoms (VMS) associated...

Update Reimbursement Scheme Elvanse®

Update Reimbursement Scheme Elvanse®

17/03/2024

TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Elvanse® 20 mg, 30 mg, 40 mg,...

Update Reimbursement Scheme Jardiance® 10mg - Chronic Kidney Disease

Update Reimbursement Scheme Jardiance® 10mg - Chronic Kidney Disease

01/02/2024

From February 1, 2024, the use of Jardiance® (empagliflozin) in adult patients with chronic kidney disease, with and without...

Reimbursement Scheme Kesimpta®

Reimbursement Scheme Kesimpta®

03/11/2023

The health insurer does not fully reimburse Kesimpta® injvlst 50mg/ml pen 0,4ml. The producer of this medicine has therefore asked...

You are currently offline. Some pages or content may fail to load.